MedTrace Logo

The DETECT Project

NCT05254106 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 250000

Last updated 2022-04-28

No results posted yet for this study

Summary

This study aims to assess the all-cause mortality at 2 years of patients treated by a paclitaxel drug-eluting devices or non-drug-eluting devices after an endovascular femoropopliteal artery revascularization based on the French National Healthcare Data System (SNDS).

Conditions

  • Femoropopliteal Atheromatous Lesions

Interventions

DEVICE

Lower limb artery revascularization with paclitaxel-eluting device

Lower limb artery revascularization with paclitaxel-eluting stent and/or paclitaxel-coated balloon

Sponsors & Collaborators

  • French-Speaking Vascular and Endovascular Surgery Society Support

    collaborator UNKNOWN

  • Boston Scientific Corporation

    collaborator INDUSTRY

  • Cook Research Incorporated

    collaborator INDUSTRY

  • Nantes University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-01
Primary Completion
2021-12-31
Completion
2024-12-31
FDA Device
Yes

Countries

  • France

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05254106 on ClinicalTrials.gov